other material
confidence high
sentiment neutral
materiality 0.50
Karyopharm files 1-for-15 reverse stock split effective Feb 25 to meet Nasdaq bid price rule
Karyopharm Therapeutics Inc.
- Reverse stock split 1-for-15 effective Feb 25, 2025 at 5pm ET; post-split trading starts Feb 26.
- Authorized shares reduced to 53,333,333; no fractional shares, cash paid in lieu.
- Equity awards, warrants, and convertible notes adjusted proportionally.
- New CUSIP number for common stock after split is 48576U205.
- Purpose: regain compliance with Nasdaq minimum $1.00 bid price continued listing requirement.